<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02888522</url>
  </required_header>
  <id_info>
    <org_study_id>15-182</org_study_id>
    <nct_id>NCT02888522</nct_id>
  </id_info>
  <brief_title>Pre-emptive Immunomodulation After Allogeneic Stem Cell Transplantation in AML</brief_title>
  <acronym>IMODLAM</acronym>
  <official_title>Pre-emptive Immunomodulation After Allogeneic Stem Cell Transplantation in AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is now an effective treatment
      of Acute Myeloid Leukemia (AML). After allo-HSCT, relapses are the major cause of mortality
      and occur in about 30% of cases. The occurrence of relapses is important during the first
      three months post-allogeneic transplant, then gradually decreases during the first year
      post-allograft and then becomes weaker. After relapse, therapeutic options include the
      reduction of immunosuppression, the administration of donor lymphocytes (DLI), chemotherapy
      or a new transplant. The performance is influenced by the early introduction of treatment
      whose effectiveness is related to the importance of tumor burden. Immunomodulation of
      preemptive strategies have recently been established by decreasing immunosuppression and
      achieve DLIs in patients with a high risk of relapse, before the occurrence of relapse.

      The aim of this study is to evaluate the incidence of relapse following the recommendations
      of post-allogeneic transplant immunomodulation of the French society of bone marrow
      transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of recipient chimerism</measure>
    <time_frame>3 months</time_frame>
    <description>whole blood chimerism</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of relapse at 1 year</measure>
    <time_frame>Relapse rate at 1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>AML</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>immunomodulation</intervention_name>
    <description>Immunomodulation depending on chimerism</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Acute myeloid leukemia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute myeloid leukemia

          -  Allogeneic stem cell transplantation (related or unrelated)

        Exclusion Criteria:

          -  Age under 18 years

          -  Cord blood transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvain P Chantepie, MD</last_name>
      <phone>+33231272073</phone>
      <email>chantepie-s@chu-caen.fr</email>
    </contact>
    <investigator>
      <last_name>Sylvain P Chantepie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2016</study_first_submitted>
  <study_first_submitted_qc>August 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2016</study_first_posted>
  <last_update_submitted>August 30, 2016</last_update_submitted>
  <last_update_submitted_qc>August 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Caen</investigator_affiliation>
    <investigator_full_name>Sylvain CHANTEPIE</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

